Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTION TREAT: Candesartan/Chlorthalidone/Amlodipine vs Exforge HCT in Hypertension
NCT05920005Phase 3Completed
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Aug 2023
- Primary completion
- Mar 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of candesartan cilexetil, chlorthalidone and amlodipine in hypertension (HTN) (2 arms), sponsored by Hospital Israelita Albert Einstein. Primary endpoint: Mean change in systolic blood pressure at 12 weeks. Started Aug 2023; status: completed.
02
Drugs
candesartan cilexetilchlorthalidoneamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05920005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05920005.